GLP-1 medications, such as Ozempic, may interact with other drugs, causing very low blood sugar levels or disrupting the ...

In addition, in the coming years, oral GLP-1 receptor agonists and injectable formulations that require less-frequent ...

Labels of all GLP-1 receptor agonists now carry a warning about pulmonary aspiration during general anesthesia or deep ...

Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...

Most patients should not stop taking GLP-1 receptor agonists prior to elective surgery, according to updated guidance from ...

In a practice-changing guideline reversal, medical societies advised on Tuesday that most patients do not need to stop taking ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Pfizer executives are still bullish on the opportunity for its own obesity and diabetes drugs under development, eyeing a potential opening for oral versions and an improved safet ...

For instance, new formulations and delivery methods, such as oral GLP-1RAs, are being developed to ... Cost remains a ...

an oral GLP-1/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 - SAN JOSE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeu ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...